Last reviewed · How we verify
Tigerase®
Tigerase is a small molecule that inhibits the activity of a specific enzyme.
Tigerase is a small molecule that inhibits the activity of a specific enzyme. Used for Type 2 diabetes.
At a glance
| Generic name | Tigerase® |
|---|---|
| Also known as | dornase alfa |
| Sponsor | AO GENERIUM |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Tigerase works by selectively targeting and blocking the activity of the enzyme, which plays a crucial role in the development of the disease it is intended to treat. This mechanism of action is thought to be responsible for the therapeutic effects of Tigerase.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 (PHASE3)
- Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tigerase® CI brief — competitive landscape report
- Tigerase® updates RSS · CI watch RSS
- AO GENERIUM portfolio CI